Drugs / HepA-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06460545 | Jun 2024 → Aug 2026 overdue | hepatitis A virus infection, poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepA-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06460545 ↗ |
| Modality | Vaccine | “live-attenuated hepatitis A virus vaccine” NCT06460545 ↗ |